IL6 and COVID-19: Furthermore, since it has been previously established that there is an elevation of inflammatory markers and a cytokine storm with high Interleukin-6 (IL-6) in severe COVID-19 patients, medications like tocilizumab and sarilumab are being investigated that could potentially reduce this effect by blocking the IL-6 for treatment in severe cases [66].